Press Releases

 
Press Releases
  Date Title and Summary View
Mar 3, 2011
NEW YORK, March 3, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced that it has selected inVentiv Clinical Solutions to manage its Phase III pivotal trial with Iferanserin and Almac Group to provide electronic patient-repor...
Feb 7, 2011
NEW YORK, Feb. 7, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, announced today that Dr. Russell Ellison, the company's president and chief executive officer will be presenting at the 2011 BIO CEO & Investor Conference on Monday, Februa...
Feb 1, 2011
NEW YORK, Feb. 1, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced the completion of its clinical development staffing. Ventrus has contracted Mohan Kabadi, Ph.D. as head of Pharmaceutical Product Development and Ma...
Jan 7, 2011
NEW YORK, Jan. 7, 2011 (GLOBE NEWSWIRE) -- Ventrus Biosciences, Inc. ("Ventrus") (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced that the underwriters of its initial public offering have exercised in full their over-allotment option to purchase an additional 435,000 sha...
Dec 23, 2010
NEW YORK, Dec. 23, 2010 (GLOBE NEWSWIRE) -- Ventrus Biosciences Inc. ("Ventrus") (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced that it closed its previously announced public offering of 2,900,000 shares of common stock. We intend to use the net proceeds from t...
Dec 16, 2010
NEW YORK, Dec. 16, 2010 (GLOBE NEWSWIRE) -- Ventrus Biosciences Inc. ("Ventrus") (Nasdaq:VTUS), a pharmaceutical company focused on developing and commercializing gastrointestinal products, today announced the pricing of its initial public offering of 2,900,000 shares at...
Page: FirstPrevious ...
8
= add release to Briefcase



The Website contains information, news and/or press releases about the Company.  While this information was believed to be accurate as of the date it was prepared, the Company disclaims any duty or obligation to update this information, news or any press releases.

Investor Contact

investors@assemblybio.com